Koneksa, a leader in designing and validating digital biomarkers to accelerate drug development, announced the completion of a $45M Series C financing round, led by AyurMaya, an affiliated fund of Matrix Capital Management, with participation from Takeda Ventures and Velosity Capital.

Existing investors McKesson Ventures, Merck Global Health Innovation Fund, Novartis (dRx Capital), Spring Mountain Capital and Waterline Ventures also joined the financing round. Koneksa has raised approximately $65M in gross proceeds from private financings to date.